Jun­shi and Co­herus plan to hus­tle the lat­est PD-1 to the FDA af­ter an up­beat PhI­II as­sess­ment

Four months af­ter its first up­beat in­ter­im analy­sis, Shang­hai’s Jun­shi Bio­sciences and Cal­i­for­nia biotech Co­herus Bio­Sciences are tout­ing a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in over­all sur­vival …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER